

**4TH EDITION**

# **IMMUNOLOGY**

## **FOR MEDICAL STUDENTS**

**Dr. Matthew Buckland, MBBS, MSc,  
PhD, FRCP, FRCPath, FHEA**

Consultant Immunologist  
Barts Health NHS Trust  
Great Ormond St Hospital for Children NHS  
Foundation Trust

Honorary Associate Professor  
UCL, London  
UK



Copyright © 2026 Elsevier LTD. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

For accessibility purposes, images in electronic versions of this book are accompanied by alt-text descriptions provided by Elsevier. For more information, see <https://www.elsevier.com/about/accessibility>.

Books and Journals published by Elsevier comply with applicable product safety requirements. For any product safety concerns or queries, please contact our authorised representative, Elsevier B.V., at [productsafety@elsevier.com](mailto:productsafety@elsevier.com).

Publisher's note: Elsevier takes a neutral position with respect to territorial disputes or jurisdictional claims in its published content, including in maps and institutional affiliations.

Previous editions copyrighted 2017, 2007, and 2002.

No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, or any information storage and retrieval system, without permission in writing from the publisher. Details on how to seek permission, further information about the Publisher's permissions policies and our arrangements with organizations such as the Copyright Clearance Center and the Copyright Licensing Agency, can be found at our website: [www.elsevier.com/permissions](http://www.elsevier.com/permissions).

This book and the individual contributions contained in it are protected under copyright by the Publisher (other than as may be noted herein).

#### Notice

Practitioners and researchers must always rely on their own experience and knowledge in evaluating and using any information, methods, compounds or experiments described herein. Because of rapid advances in the medical sciences, in particular, independent verification of diagnoses and drug dosages should be made. To the fullest extent of the law, no responsibility is assumed by Elsevier, authors, editors or contributors for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein.

ISBN 978-0-7020-8434-8

*Sr. Content Strategist:* Alexandra Mortimer  
*Sr. Content Development Specialist:* Suddha Satwa Sen  
*Book Specialist:* Kamatchi Madhavan  
*Design:* Ryan Cook  
*Marketing Manager:* Belinda Tudin

Printed in India

Last digit is the print number: 9 8 7 6 5 4 3 2 1



# CONTENTS

## SECTION 1 Introduction

---

- 1 Introduction to the Immune System, 2
- 2 Basic Concepts and Components of the Immune System, 7

## SECTION 2 Antigen-Recognition Molecules

---

- 3 Introduction to Antigen Recognition, 16
- 4 Antigens and Antibody Structure, 20
- 5 Antibody-Antigen Interaction, 27
- 6 Antibody Diversity, 37
- 7 The T-Cell Receptor, 47
- 8 Major Histocompatibility Complex, 54
- 9 Review of Antigen Recognition, 62

## SECTION 3 Physiology

---

- 10 Antigen Processing and Presentation, 66
- 11 Lymphocyte Activation, 72
- 12 Hematopoiesis, 80
- 13 Organs and Tissues of the Immune System, 86
- 14 B-Cell Development, 96
- 15 T-Cell Development, 103
- 16 T-Cell Interactions and T-Cell Help, 113
- 17 Immunologic Memory and Homeostasis, 124
- 18 Regulation of the Immune System, 130
- 19 Brief Review of Immune Physiology, 136

## SECTION 4 Innate Immunity

---


- 20 Constitutive Defenses Including Complement, 141
- 21 Phagocytes, 152
- 22 Killing in the Immune System, 164
- 23 Inflammation, 174
- 24 Cytokines in the Immune System, 184

## SECTION 5 Immune System in Health and Disease


---

- 25 Infections and Vaccines, 193
- 26 Hypersensitivity Reactions, 202
- 27 Immediate Hypersensitivity (Type I): Allergy, 208
- 28 How Autoimmune Disease Develops, 219
- 29 Antibody-Mediated Hypersensitivity (Type II), 233
- 30 Immune Complex Disease (Type III Hypersensitivity), 240
- 31 Delayed Hypersensitivity (Type IV) and Review of Hypersensitivity Reactions, 247
- 32 Primary Immunodeficiency, 255
- 33 Secondary Immunodeficiency, 265
- 34 Transplantation, 274
- 35 Tumor Immunology, 284
- 36 Biopharmaceuticals, 294

Index, 303



**Fig. 1.2** Clonal selection of B cells.



**Fig. 1.3** Scanning electron micrograph of T cells (*blue*) and a tumor cell (*red*). (From BSIP Lecaue and the Science Photo Library.)

B cells, the daughter clones produce large amounts of soluble receptor (antibody). In the case of T cells, large numbers of specific effector cells bearing the appropriate receptor on their cell surface are generated. Different types of specialist T cells, such as T-helper (TH) cells, are produced for specific situations (see [Chapter 16](#)). For example, TH1 T cells are usually produced in response to viral infections, TH2 T cells are produced in response to worms, and TH17 cells respond to fungi and extracellular bacteria.

B-cell and T-cell antigen receptors differ in one very important way: B-cell antigen receptors can interact directly with antigen, whereas T-cell antigen receptors recognize an antigen only when it is presented to them on the surface of another cell by MHC molecules (see [Chapters 2, 7, and 8](#)).

In addition to recognizing nonself antigens, the cells of the immune system also recognize alterations of self that result from certain disease processes—for example, modified self-antigens found on tumor cells—and may eliminate the tumor cell once it has been recognized ([Fig. 1.3](#); see [Chapter 35](#)). The ability to recognize unaltered self-antigen can, if unregulated, lead to autoimmune disease, such as with some forms of diabetes mellitus (see [Chapter 28](#)). Fortunately, the adaptive immune

**TABLE 1.1 Comparison of Some Overall Features of the Innate and Adaptive Immune Systems**

	Innate	Adaptive
Characteristics	Nonspecific response Fast response (minutes) No memory	Very specific Slow response (days) Memory
Components	Natural barriers, phagocytes, and secreted molecules Few pattern-recognition molecules	Lymphocytes and secreted molecules Many antigen recognition molecules

system contains a number of mechanisms to ensure that unaltered self-antigens are tolerated, which prevents autoimmune disease in most people (see [Chapter 18](#)).

A critically important feature of the adaptive immune response is that it displays memory of a previous encounter with a microbe (or antigen). This is the basis of protection from disease by vaccination with an attenuated form of the pathogen ([Box 1.2](#); see also [Box 2.1](#)), but it is also the way in which the body is protected from reinfection. For example, we are regularly exposed to coronaviruses ([Box 1.3](#)). If we reencounter the same antigenic form of coronavirus, or even an antigenically similar (i.e., cross-reactive) form, the response is faster and greater in magnitude, and infection is limited or prevented. Unfortunately, because coronaviruses are one of a class of infectious agents capable of radically changing their genetic structure (and antigenic makeup), new viruses are always around to cause new infections. The most obvious example of this is from the SARS-CoV-2 or COVID-19 pandemic. Several overall characteristics of the innate and adaptive immune systems are summarized in [Table 1.1](#).

The medical successes associated with advances in knowledge about the host defense system include improvements in public health that have arisen from vaccination against communicable diseases (see [Box 1.2](#) and [Chapter 25](#)); success with organ transplantation, such as with kidneys and hearts (see [Box 1.4](#) and



- Activation phase.** Phase of the immune response when a lymphocyte divides to give many more of the same cell (clonal expansion).
- Active immunity.** Protective immunity that develops after exposure to infection or vaccination.
- Acute-phase response.** A systemic reaction to infection or inflammation, mediated by cytokine production and characterized by fever and production of acute-phase proteins.
- Adaptive (acquired) immune system response.** Part of the immune system in which genetic recombination is used to recognize specific molecules. Slow to respond, but produces lasting memory.
- Adjuvant.** Substance that increases the immunogenicity of a vaccine, usually by activating the innate immune system.
- Affinity.** Strength of binding between antigen and antibody or T- or B-cell receptor.
- Affinity maturation.** Process by which B cells undergo somatic hypermutation and increase the affinity of the B-cell receptor.
- Allele.** Normal genetic variants that occur in more than 1% of the population. For example, eye color or different human leukocyte antigen types.
- Allelic exclusion.** Any one B cell expresses only immunoglobulin of one allotype in a heterozygous individual.
- Allergen.** An environmental substance capable of eliciting an immediate hypersensitivity reaction.
- Allergy.** Immediate hypersensitivity reaction to an otherwise harmless environmental substance, mediated by immunoglobulin E.
- Allogeneic.** Immune reactions to a genetically different member of the same species.
- Allogeneic transplant.** Transplant between genetically different members of the same species.
- Allotype.** Genetic polymorphisms (different alleles) of both heavy and light chain immunoglobulin genes that can be detected by antibodies.
- Alternative pathway.** Activation of the complement cascade by exposure to a solid surface lacking complement inhibitors.
- Anaphylatoxin.** Low-molecular-weight product of complement activation that increases capillary permeability and attracts leukocytes.
- Energy.** State of dormancy induced by exposure to antigen in certain circumstances.
- Antibody.** Protein produced in response to and capable of binding specifically with an antigen. Antibodies have an immunoglobulin structure.
- Antigen.** Molecules specifically recognized by receptors of the adaptive immune system.
- Antigen recognition molecules (ARMs).** The ARMs are the B- and T-cell receptor molecules and the proteins encoded by the major histocompatibility complex.
- Antigen-binding site.** The portion of the antibody that makes contact with antigen.
- Antigenemia.** High levels of antigen circulating in the bloodstream.
- Antigenic drift.** Gradual change in an organism's antigens consequent to acquisition of mutations.
- Antigen-presenting cells (APCs).** Cells that can process antigen and present antigen to T cells.
- Apoptosis.** Deliberate, programmed cell death.
- Asthma.** Transient airflow limitation due to bronchial smooth muscle constriction and mucus secretion.
- Atopy.** Genetic predisposition to allergy.
- Attenuated vaccine.** Vaccine produced by genetically modifying a pathogenic organism.
- Autoantibody.** Antibody produced against self antigen.
- Autoimmune disease.** Disease caused by hypersensitivity reactions that occur as exaggerated autoimmunity.
- Autoimmunity.** Recognition of normal components of the body by the adaptive immune system. Occurs in healthy individuals but can also cause autoimmune disease.
- Autologous transplant.** Tissue returning to the same individual after a period outside the body, usually in a frozen state.
- B-cell receptor (BCR).** The cell surface-located receptor for antigen on B cells.
- B lymphocytes.** Subset of white blood cells that can secrete antibody molecules.
- Bence Jones protein.** Monoclonal light chain present in the urine in myeloma.
- Biopharmaceutical (biologic).** Medication, usually proteins, produced by living cells.
- Biosimilar.** Two biopharmaceuticals with identical amino acid sequences but produced by different manufacturers. Cannot be assumed to be identical.
- Blasts.** Immature, rapidly proliferating cells.
- Bone marrow.** The major hematopoietic organ in humans. Particularly important in B-cell generation, but all the blood cell types—except mature T cells—are generated in the bone marrow.
- Caspase.** Proteolytic enzymes involved in triggering apoptosis.
- CD.** Cluster of differentiation nomenclature system for cell surface molecules (and thus for cell subsets).
- CD4 count.** Number of circulating CD4<sup>+</sup> T cells; used to monitor HIV infection.
- Cell-mediated immunity.** Refers to the function of T cells as opposed to humoral or antibody-mediated immunity.
- Central tolerance.** Tolerance induced in immature T or B cells in the thymus and bone marrow, respectively.
- Chemokines.** Chemotactic cytokines; these attract cells to the site of infection.
- Chemotaxis.** Directed movement of cells, often to the site of infection.
- Chimeric monoclonal antibody.** Monoclonal antibody using mouse immunoglobulin variable regions and human immunoglobulin constant regions.
- Class switching.** The process by which an individual B cell can, during maturation, switch immunoglobulin heavy chain usage while retaining the same variable genes and antigen specificity.
- Classical pathway.** Activation of the complement cascade by exposure to aggregated immunoglobulin.
- Clonal selection theory.** The idea that each lymphocyte expresses a unique antigen receptor and that this preexisting cell divides on exposure to antigen and gives rise to many daughter cells (clones).
- Clone.** In immunology, a series of genetically identical lymphocytes, all derived from one B cell or T cell after receptor recombination.
- Cognate antigen.** The precise antigen that a given antigen receptor has specificity for.
- Cognitive phase.** Phase of an active immune response during which antigen is recognized by a cell bearing a receptor specific for the antigen.
- Collectin.** Molecules forming part of the innate immune system, containing lectin (carbohydrate-binding) domains and collagen-like domains.
- Colony-stimulating factor (CSF).** Growth factors that induce differentiation of specific cell lineages during hematopoiesis.
- Combinatorial diversity.** Refers to immunoglobulin or T-cell receptor variable region gene segments recombining in multiple combinations (e.g., 30 V $\kappa$   $\times$  5 J $\kappa$  = 150 different variable regions).
- Complement.** Cascade of serum enzymes activated by the presence of pathogens.
- C-reactive protein (CRP).** Acute-phase protein produced at high levels during inflammation.
- Cross-reactivity.** Occasionally, an antigen recognition molecule is specific for a particular antigen, but a different antigen fits well enough for stable binding to occur.

Page numbers followed by “f” indicate figures, “t” indicate tables, and “b” indicate boxes.

## A

ABO antigen system, [233](#), [234f](#)  
 Accessory molecules, [74](#)  
   involved in T-cell function, [50–51](#), [51f](#)  
 Activation-induced cell death (AICD), [132](#)  
 Activation phase, of immune response, [9](#)  
 Activation protein [1](#) (AP-[1](#)), [77](#)  
 Active cancer immunotherapy, [289](#), [292f](#)  
 Active immunity, [9](#), [25b](#), [25f](#), [194–195](#)  
 Acute-phase response, [158](#)  
 Acute rejection, [275–276](#), [276f](#), [281b](#), [281f](#)  
 Adaptive immune system, [2](#). *See also* Innate immune system  
   *versus* innate immune system, [4t](#), [141](#), [142t](#)  
   toll-like receptors, role of, [138f](#), [139b](#)  
 Adjuvants, [196](#), [201b](#)  
 Adrenaline. *See* Epinephrine  
 Affinity maturation, [43](#), [99–100](#)  
 Aging immune system, [270–271](#), [270f](#)  
 Airways, allergic diseases affecting, [210t](#)  
 Allelic exclusion, [40](#)  
 Allergens, [21](#), [209](#)  
 Allergic diseases, [208](#), [210t](#)  
 Allergic march, [208–209](#)  
 Allergy, [202](#), [203](#). *See also* Hypersensitivity, type [I](#)  
 Alloantigen, [21](#)  
 Allogeneic transplant, [275](#)  
 Alveolar macrophages, [154](#)  
 Anaphylatoxins, [145–146](#), [147f](#), [155](#)  
 Anaphylaxis, [210t](#)  
 Anchor residues, [57](#)  
 Anergy, [78](#), [97](#), [131](#)  
 Angioedema, [210t](#)  
   hereditary, [150b](#), [150f](#)  
 Ankylosing spondylitis, [60](#)  
 Antibiotics,  $\beta$ -lactam ring and, [209](#)  
 Antibody(ies), [17](#), [20–26](#), [219](#), [220](#)  
   and antigen interaction, [27–36](#)  
   binding sites of, [28](#), [28f](#)  
   to diagnose acute hepatitis B infection, [44b](#), [44f–45f](#), [45t](#)  
   diagnostic tests for, [28–36](#)  
     enzyme-linked immunosorbent assay, [28](#), [29f](#)  
     flow cytometry, [29–31](#), [34f](#)  
     immunofluorescence, [29](#), [31f](#), [32f](#), [33b–34b](#)  
     lateral flow test, [28–29](#), [33f](#)  
   diversity of, [37–46](#)

Antibody(ies) (*Continued*)  
   generation of, [41–43](#), [42t](#)  
   immunoglobulin genes, [37–43](#), [38f](#)  
   in immune complexes, [241f](#), [242](#)  
   isolation and characterization of, [21–22](#), [22f](#)  
   monoclonal. *See* Monoclonal antibodies  
   natural, [220](#), [220f](#)  
     B1 B cells and, [101](#), [101t](#)  
     response, to HIV, [267](#), [268f](#)  
     structure of, [20–26](#)  
 Antigen-presenting cells (APCs), [9](#), [12f](#), [67](#), [67f](#), [82](#)  
 Antigen receptors, [73–75](#), [73f](#)  
   B-cell receptor, [73](#), [73f](#)  
   T-cell receptor, [73](#)  
 Antigen recognition, [15–19](#), [62–64](#)  
   generation of diversity, [63t](#), [64](#), [64t](#)  
   molecules, [17](#), [17f](#)  
   sites of, [63](#)  
 Antigenemia, [241](#)  
 Antigen(s), [3](#), [3–4](#), [20–21](#)  
   ABO blood group, [233](#), [234f](#)  
   and antibody interaction, [27–36](#)  
   binding sites of antibodies, [28](#), [28f](#)  
   cognate, [91](#), [106](#)  
   diagnostic tests for, [28–36](#)  
     enzyme-linked immunosorbent assay, [28](#), [29f](#)  
     flow cytometry, [29–31](#), [34f](#)  
     immunofluorescence, [29](#), [31f](#), [32f](#), [33b–34b](#)  
     lateral flow tests, [28–29](#), [33f](#)  
   extracellular, [67–68](#), [68f](#)  
   in immune complexes, [241–242](#), [241f](#)  
   intracellular, [68–70](#), [68f](#)  
   leukocyte function-associated, [50–51](#)  
   naive T-cell activation by, [106–112](#), [110f](#)  
   presentation of, [65–71](#)  
   processing, [9](#), [65–71](#)  
     class I/II association, [68f](#), [69f](#), [70](#), [70t](#)  
     mechanism of, [67–70](#)  
     pathways of, [67](#)  
   recognition of, by T lymphocytes, [67](#)  
   rhesus, [233](#), [233–234](#), [234f](#), [235](#), [237b](#), [238f](#)  
   self, [97](#)  
     hypersensitivity to, [203](#)  
   structural features of, [63–64](#)  
     immunoglobulin domain fold, [63](#), [63f](#)  
   structure of, [20–26](#)  
   thymus-independent, [100–101](#), [101f](#)

Antigen(s) (*Continued*)  
   transplantation, graft rejection and, [60b](#), [60f](#)  
   types of, [20–21](#)  
 Antihistamines, for allergies, [214](#)  
 Antiinflammatory drugs, [250](#)  
 Antiproliferatives, [278](#)  
 APCs. *See* Antigen-presenting cells (APCs)  
 Apoptosis, [78](#), [127–128](#), [127f](#), [128b](#), [128t](#), [145](#)  
   in immune system, [171](#), [171t](#), [172t](#)  
   intracellular mechanisms of, [170–173](#), [173f](#)  
   and necrosis, comparison of, [171t](#)  
 Arachidonic acid metabolites, mast cell  
   source of, [166–167](#)  
 Arthus reaction, immune complexes and, [241](#), [245b](#), [245f](#)  
 Asthma, [210t](#)  
 Atopic eczema, [208–209](#), [210t](#)  
   peanut allergy with, [217b](#), [217f](#)  
 Atopy, [208](#)  
 Atopy trait, [210](#)  
 Autoantigens, [21](#), [219](#)  
 Autoimmune disease, [219–232](#)  
   initiation of, [220–221](#)  
   risk factors for, [223t](#)  
   T-cell tolerance in, [221–222](#), [223f](#)  
     breakdown of, [222–223](#), [222f](#)  
     environmental factors and loss of tolerance, [222–223](#), [223f](#), [229b–231b](#), [229f](#), [230f](#), [231f](#), [232f](#)  
     genetic factors and loss of tolerance, [222](#), [223f](#)  
   tests for, [223–224](#), [224b–225b](#), [224f](#), [225f](#), [226f](#), [229b–231b](#), [229f](#), [230f](#), [231f](#), [232f](#)  
 Autoimmune polyendocrinopathy candidiasis ectodermal dysplasia (APECED) syndrome, [105](#), [109f](#), [110b](#)  
 Autoimmunity, [219](#), [220f](#)  
 Autologous hematopoietic stem cell transplantation, [84b](#)  
 Autologous transplant, [274](#)

## B

B-cell receptors, [17](#), [73](#), [73f](#)  
 B cells. *See also* Antibody(ies); Immunoglobulin(s)  
   activation of  
     coreceptor molecules in, [73f](#), [74](#)  
     initiation of, [74](#)